semaglutide age Semaglutide-related death reports distribution by gender and groups A new study linked semaglutide

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been pivotal for obesity treatment, achieving 1525 % weight loss over 1224 months, but questions remain about the potential influence of concomitant losses in muscle mass

A clear 2025 head-to-head comparison of Wegovy and Zepbound plus how to decide with your clinician.

You did it

To explore the therapeutic potential of GLP-1RAs across PCOS phenotypes, we employed a hyperandrogenism-induced rat model and a letrozole plus high-fat diet mouse model, treating them with exenatide or semaglutide, respectively

Promotes GLP-1 activity to naturally enhance fullness, reduce cravings, and improve glycemic response

Doctor-supervised GLP-1 weight loss in Pasadena with FDA-approved medications